Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2010 1
2011 2
2012 2
2013 3
2014 2
2015 2
2016 3
2017 4
2018 4
2019 1
2020 4
2021 9
2022 10
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Learning imaging in axial spondyloarthritis: more than just a matter of experience.
Radny F, Ziegeler K, Eshed I, Greese J, Deppe D, Stelbrink C, Biesen R, Haibel H, Rios Rodriguez V, Rademacher J, Protopopov M, Proft F, Hermann KGA, Poddubnyy D, Diekhoff T, Ulas ST. Radny F, et al. Among authors: biesen r. RMD Open. 2024 Mar 4;10(1):e003944. doi: 10.1136/rmdopen-2023-003944. RMD Open. 2024. PMID: 38443089 Free article.
Self-reported diagnostic confidence predicts diagnostic accuracy in axial spondyloarthritis imaging.
Ulas ST, Radny F, Ziegeler K, Eshed I, Greese J, Deppe D, Stelbrink C, Biesen R, Haibel H, Rios Rodriguez V, Rademacher J, Protopopov M, Proft F, Poddubnyy D, Diekhoff T. Ulas ST, et al. Among authors: biesen r. Rheumatology (Oxford). 2023 Oct 26:kead564. doi: 10.1093/rheumatology/kead564. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37882740
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Vital E, Versnel M. Rodríguez-Carrio J, et al. Among authors: biesen r. RMD Open. 2023 Mar;9(1):e002864. doi: 10.1136/rmdopen-2022-002864. RMD Open. 2023. PMID: 36882218 Free PMC article.
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Burska A, Rodríguez-Carrio J, Biesen R, Dik WA, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Conaghan PG, Versnel M, Vital E. Burska A, et al. Among authors: biesen r. RMD Open. 2023 Mar;9(1):e002876. doi: 10.1136/rmdopen-2022-002876. RMD Open. 2023. PMID: 36863752 Free PMC article.
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Rönnblom L, Versnel MA, Vital EM. Rodríguez-Carrio J, et al. Among authors: biesen r. Ann Rheum Dis. 2023 Jun;82(6):754-762. doi: 10.1136/ard-2022-223628. Epub 2023 Mar 1. Ann Rheum Dis. 2023. PMID: 36858821
Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients.
Ten Hagen A, Hermann S, Habermann E, Frommert LM, Arumahandi de Silva AN, Scholz V, Ghannam K, Klotsche J, Zernicke J, Alexander T, Burmester GR, Albach FN, Biesen R. Ten Hagen A, et al. Among authors: biesen r. J Autoimmun. 2023 Feb;135:102996. doi: 10.1016/j.jaut.2023.102996. Epub 2023 Jan 9. J Autoimmun. 2023. PMID: 36642057 Free PMC article.
52 results